(ATNM) Actinium Pharmaceuticals, Inc. Business Model Canvas Research

AVEO Oncology’s HER3 ARC partnership gives Actinium Pharmaceuticals, Inc. a validated solid-tumor target beyond CD45 and CD33, widening the platform into HER3 (ERBB3)-driven cancers. It also adds external development leverage, which can speed preclinical work and reduce internal burn.

• Targets solid tumors with HER3
• Diversifies beyond CD45 and CD33
• Adds outside development capacity

Actinium depends on bone marrow transplant and cell therapy centers to run its clinical programs, enroll patients, and execute protocols. These sites also drive physician adoption, which is key for turning conditioning assets into routine real-world use.

• Support patient enrollment
• Run trial protocols
• Build physician adoption
• Enable real-world use

Actinium Pharmaceuticals, Inc. validates CD45, CD33, CD38, CD47, HER2, and HER3 because these are proven cancer markers across blood and solid tumors, helping link each isotope to the right target. This target fit matters for its radiopharma model, where precision can improve tumor kill and limit off-target exposure.

• CD45/CD33/CD38: hematologic cancers
• CD47/HER2/HER3: broad solid-tumor reach
• Target match drives isotope use

Actinium Pharmaceuticals, Inc. runs trial ops, FDA/EMA regulatory filings, and CMC work to keep its clinical pipeline moving; as a clinical-stage biotech, it had no product revenue in its latest filings, so execution here is core to value creation. One delayed IND, amendment, or batch release can stall a program.

• Trial management across active studies
• Regulatory filings and agency responses
• CMC planning, testing, and supply coordination

Actinium Pharmaceuticals, Inc. relies on clinical and regulatory expertise to move its 1 lead radiotherapeutic program through complex oncology trials and FDA review. As a clinical-stage developer with no marketed products, its value sits in trial design, safety execution, and regulatory planning that can shorten development risk for late-stage, high-complexity assets.

• Clinical-stage, not commercial
• 1 lead radiotherapeutic program
• Trial design and oncology execution
• Regulatory work is mission-critical

Actinium Pharmaceuticals, Inc. is headquartered in New York, New York, and the company was incorporated in 2000. That New York base supports corporate, scientific, and partnership work, which matters for a clinical-stage biotech that needs close coordination across research and deal-making.

• New York headquarters
• Incorporated in 2000
• Supports science and partnerships

Actinium Pharmaceuticals, Inc. uses radioisotopes to hit defined cancer markers, so the value proposition is precision oncology with higher selectivity than non-targeted treatment. Its lead programs, built around validated targets such as CD33 and CD45, aim to deliver payloads only where the cancer cells are, which is the core edge versus broad chemotherapy.

• Targeted radioisotopes, not blanket exposure
• Precision oncology positioning
• Designed to improve selectivity

Actinium Pharmaceuticals can reuse one radiopharmaceutical platform across blood cancers and solid tumors, so the same targeting and payload logic can support more than one market. That breadth matters: Actinium Pharmaceuticals had 2 clinical-stage programs in its pipeline, giving it both a near-term hematologic focus and a longer-run solid-tumor option.

• One core radiopharmaceutical platform
• Works across multiple indications
• Pipeline spans blood and solid tumors
• 2 clinical-stage programs

Academic collaboration is central to Actinium Pharmaceuticals, Inc., because early radiopharmaceutical work needs translational input from cancer centers and trial sites. In its recent clinical programs, that model has supported phase 1/2 testing in patients where real-world academic expertise helps refine dose, safety, and biomarker readouts for novel radionuclides.

• Drives early clinical testing
• Supports translational insight
• Fits complex radiopharmaceuticals

Actinium Pharmaceuticals, Inc. reaches patients through trial sites and care teams, so the relationship is tightly managed and highly specialized. Because its therapies involve eligibility checks, transplant planning, and study follow-up, support must stay close to each patient’s clinical path.

• Site-led patient outreach
• Complex therapy support
• Eligibility and transplant planning
• Ongoing study follow-up

Scientific publications and congresses are a high-value channel for Actinium Pharmaceuticals, Inc. in oncology, where adoption is driven by trial data, peer review, and KOL trust. ASCO 2025 drew over 40,000 attendees, showing how one meeting can amplify awareness, support investigator interest, and open partner talks.

• Build awareness through peer-reviewed data.
• Use congresses to reach oncology KOLs.
• Support investigator and partner interest.

Actinium Pharmaceuticals, Inc. reaches hospitals through partner organizations and trial sites, not a large commercial sales force. That keeps the model lean: collaborators widen the development footprint, while clinical sites are the main link to doctors and patients in Phase 2 and Phase 3 studies.

• Partners extend reach.
• Sites run patient access.
• Sales force stays small.

Biopharma development partners like Astellas, EpicentRx, and AVEO want differentiated oncology assets plus radiopharmaceutical know-how. For Actinium Pharmaceuticals, Inc., these deals can bring non-dilutive value through upfront cash, milestones, and shared development risk; a single partnered oncology program can cut internal burn by millions while keeping upside.

• Differentiated oncology assets
• Radiopharmaceutical expertise
• Non-dilutive funding

Elderly relapsed/refractory AML patients are Iomab-B's core clinical segment. In older AML, transplant eligibility is often limited by age and frailty, and global AML 5-year survival remains near 30% overall, so unmet need before transplant is high.

• Core Iomab-B patients
• Few pre-transplant options
• High unmet need drives demand

Actinium Pharmaceuticals, Inc. G&A covers personnel, finance, legal, and corporate ops, plus the higher reporting and governance load of a public biotech. Its New York headquarters keeps these costs mostly fixed, so they stay under pressure even when R&D spend moves.

• Staff, finance, legal, ops
• Public-company reporting burden
• New York HQ fixed cost base

Oncology radiopharmaceuticals face tight FDA and nuclear safety oversight, so Actinium Pharmaceuticals, Inc. must fund regulatory filings, safety monitoring, and cGMP quality systems as each program moves from preclinical work into Phase 1, Phase 2, and Phase 3. Costs usually rise fastest in late-stage trials, when patient monitoring, radioactivity handling, and batch release testing all become more complex.

• More clinical stages, higher compliance spend
• Ongoing safety and quality checks
• Regulatory work adds fixed overhead

Royalties on future sales are Actinium Pharmaceuticals, Inc.'s long-tail upside: if a partnered asset reaches market, royalty income can start, but only after successful development, approval, and launch. As of the latest public filings available through 2025, this stream is still contingent and has not yet become a material revenue source.

• Upside starts after launch
• Depends on partner success
• Currently contingent, not recurring

Actinium Pharmaceuticals, Inc. has no approved product sales yet, so this revenue stream is still zero from marketed drugs. As a clinical-stage company, cash comes mainly from collaboration, licensing, and development economics, with product sales only a future option.

• Zero current product sales
• Revenue tied to partnerships
• Commercial sales remain future-only